New hope for pancreatic cancer? early trial combines targeted drug with chemo
NCT ID NCT06182072
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This early-phase trial tests a new drug called ProAgio alongside standard chemotherapy (gemcitabine and nab-paclitaxel) with or without an immunotherapy drug (atezolizumab) in people with advanced pancreatic cancer that has spread. The main goals are to find a safe dose and see how well the combination works. About 46 adults whose cancer has not been treated yet will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
O'Neal Comprehensive Cancer Center, University of Alabama
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.